Boulder Diagnostics Inc. and the Department of Internal Medicine, Radboud University Nijmegen Medical Centre (RUNMC) announced today the entry into a license and collaboration agreement to market the innovative Lyme disease diagnostic test developed at RUNMC. Under the agreement Boulder will finance further research at the Department of Internal Medicine, and RUNMC will be entitled to royalties on future sales of the licensed technology. Further details were not disclosed.
“The collaboration with Boulder Diagnostics allows us to extend the benefit of our innovative diagnostic technology beyond our institution”
The new powerful Lyme disease diagnostic test is particularly suited to detect a chronic Lyme infection from a patient blood sample. By reading out unique biological responses the new test can achieve unprecedented specificity without requiring invasive biopsy procedures. It avoids the notoriously low accuracy of typical serology based tests.
"We are excited to work with the Internal Medicine Department of Radboud University Nijmegen Medical Centre to bring this transformative and reliable Lyme disease test to the market in the near future", says Wolfgang Pieken, CEO of Boulder Diagnostics Inc.
"The collaboration with Boulder Diagnostics allows us to extend the benefit of our innovative diagnostic technology beyond our institution", comments Leo Joosten, Associate Professor of Experimental Medicine at Radboud University Nijmegen Medical Centre. "This assay holds the potential to significantly reduce the frequent misdiagnosis of chronic borrelia infection", adds Mihai Netea, Professor of Experimental Medicine.
Boulder Diagnostics and Radboud University Nijmegen Medical Center